Kairos Pharma (NYSEAMERICAN:KAPA) Coverage Initiated by Analysts at Maxim Group

Analysts at Maxim Group assumed coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research report issued on Thursday,Benzinga reports. The firm set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price target points to a potential upside of 330.11% from the company’s current price.

Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 price objective on shares of Kairos Pharma in a report on Thursday, March 20th.

Kairos Pharma Trading Down 3.1 %

Shares of KAPA traded down $0.03 during trading hours on Thursday, hitting $0.93. The stock had a trading volume of 9,385 shares, compared to its average volume of 2,468,510. Kairos Pharma has a 12-month low of $0.85 and a 12-month high of $4.00. The stock has a fifty day simple moving average of $1.30.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.